FDA Grants Aleva Approval for IDE Study
U.S. FDA grants Aleva Neurotherapeutics approval for an Investigational Device Exemption (IDE) study on directSTIM™ Directional Deep Brain Stimulation System Aleva is committed to starting the PMA trial in the next quarters, in parallel with the post-market clinical follow-up study currently underway in select European neurological clinics. The US trial will include up to 15 […]